ADMA Biologics (NASDAQ:ADMA) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ADMA Biologics (NASDAQ:ADMA) in a report issued on Tuesday,Benzinga reports. They currently have a $25.00 price target on the biotechnology company’s stock.

A number of other research analysts have also issued reports on ADMA. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Trading Up 7.5 %

Shares of ADMA stock opened at $17.01 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics has a 1 year low of $5.69 and a 1 year high of $23.64. The stock has a fifty day moving average of $16.68 and a two-hundred day moving average of $17.97. The firm has a market capitalization of $4.02 billion, a PE ratio of 60.75 and a beta of 0.75.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently modified their holdings of the stock. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics during the third quarter worth $30,000. Larson Financial Group LLC purchased a new stake in ADMA Biologics in the 3rd quarter worth about $31,000. GAMMA Investing LLC lifted its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI purchased a new stake in ADMA Biologics in the 3rd quarter worth about $35,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics in the 4th quarter worth about $35,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.